HealthStream (HSTM)
(Delayed Data from NSDQ)
$31.45 USD
+0.26 (0.83%)
Updated Dec 20, 2024 04:00 PM ET
After-Market: $31.47 +0.02 (0.06%) 7:58 PM ET
2-Buy of 5 2
C Value A Growth B Momentum A VGM
Price, Consensus and EPS Surprise
HSTM 31.45 +0.26(0.83%)
Will HSTM be a Portfolio Killer in December?
Zacks Investment Research is releasing its prediction for HSTM based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for HSTM
HSTM or ZS: Which Is the Better Value Stock Right Now?
HealthStream, Inc. (HSTM) Hit a 52 Week High, Can the Run Continue?
HSTM: What are Zacks experts saying now?
Zacks Private Portfolio Services
HealthStream, Inc. (HSTM) Soars to 52-Week High, Time to Cash Out?
New Strong Buy Stocks for October 31st
HealthStream (HSTM) Surpasses Q3 Earnings Estimates
Other News for HSTM
Miller-Howard Small Cap Dividend Q3 2024 Commentary
HealthStream (HSTM) Receives a Buy from Craig-Hallum
Balanced Outlook: Hold Rating Amid Strong Revenue Growth and Cautious Valuation
HealthStream price target raised by $1 at Canaccord, here's why
HealthStream price target raised by $2 at Barclays, here's why